XML 36 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair value of financial instruments and investments - Narrative (Details)
12 Months Ended
Dec. 31, 2019
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
Sep. 30, 2019
USD ($)
May 31, 2019
USD ($)
$ / shares
Aug. 23, 2018
USD ($)
Apr. 30, 2018
$ / shares
Aug. 31, 2015
USD ($)
Financial assets and liabilities measured at fair value on recurring basis                
Share price (in USD per share) | $ / shares             $ 27.04  
Unrealized (gains) losses of MRI investment $ 2,194,000 $ 0 $ 0          
Investment In MRI 6,200,000              
Marketable securities 398,535,000 58,088,000            
Contingent consideration payable 356,300,000 310,240,000            
Deferred consideration payable- current 40,000,000 19,400,000            
3.00% Convertible senior notes due 2022 | Convertible debt                
Financial assets and liabilities measured at fair value on recurring basis                
Principal 150,000,000 150,000,000           $ 150,000,000.0
Interest rate               3.00%
Debt instrument 171,200,000 146,600,000            
Convertible Senior Notes, 1.5%, Due September 15, 2026 | Convertible debt                
Financial assets and liabilities measured at fair value on recurring basis                
Principal $ 287,500,000     $ 287,500,000        
Interest rate 1.50%     1.50%        
Debt instrument $ 335,000,000.0              
Stock Appreciation Rights (SARs)                
Financial assets and liabilities measured at fair value on recurring basis                
Contingent consideration payable- net sales milestones and royalties $ 3,186,000 $ 3,814,000            
Stock Appreciation Rights (SARs) | Minimum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input | $ / shares 6.76 6.76            
Stock Appreciation Rights (SARs) | Maximum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input | $ / shares 30.86 30.86            
Stock Appreciation Rights (SARs) | Volatility | Minimum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input 0.2893 0.4653            
Stock Appreciation Rights (SARs) | Volatility | Maximum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input   0.5959            
Stock Appreciation Rights (SARs) | Risk free interest rate | Minimum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input 0.0019 0.0244            
Stock Appreciation Rights (SARs) | Risk free interest rate | Maximum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input   0.0263            
Stock Appreciation Rights (SARs) | Expected life | Minimum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input 0.01 0.01            
Stock Appreciation Rights (SARs) | Expected life | Maximum                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input 1.01 1.01            
Common stock | Stock Appreciation Rights (SARs) | Fair value of common stock                
Financial assets and liabilities measured at fair value on recurring basis                
Measurement input | $ / shares 48.03 34.32            
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2                
Financial assets and liabilities measured at fair value on recurring basis                
Marketable securities $ 398,535,000 $ 58,088,000            
Deferred consideration payable 40,000,000 37,700,000            
Stock appreciation rights liability 0 0            
Contingent consideration payable   0            
Contingent consideration payable- net sales milestones and royalties   0            
Agilis                
Financial assets and liabilities measured at fair value on recurring basis                
Development milestone payment obligations 40,000,000.0         $ 40,000,000.0    
Deferred consideration payable           38,100,000    
Agilis | Maximum                
Financial assets and liabilities measured at fair value on recurring basis                
Development milestone payment obligations 60,000,000.0              
Priority review voucher amount 535,000,000.0              
Agilis | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2                
Financial assets and liabilities measured at fair value on recurring basis                
Contingent consideration payable 0              
Contingent consideration payable- net sales milestones and royalties 0              
Non-collaborative Arrangement Transactions | Agilis                
Financial assets and liabilities measured at fair value on recurring basis                
Development milestone payment obligations 40,000,000.0         $ 40,000,000.0    
Total | Fair Value, Measurements, Recurring                
Financial assets and liabilities measured at fair value on recurring basis                
Marketable securities 398,535,000 58,088,000            
Deferred consideration payable 40,000,000 37,700,000            
Stock appreciation rights liability 3,186,000 3,814,000            
Contingent consideration payable   257,040,000            
Contingent consideration payable- net sales milestones and royalties   $ 53,200,000            
Total | Agilis | Fair Value, Measurements, Recurring                
Financial assets and liabilities measured at fair value on recurring basis                
Contingent consideration payable 290,500,000              
Contingent consideration payable- net sales milestones and royalties 65,800,000              
Common stock                
Financial assets and liabilities measured at fair value on recurring basis                
Purchase investment         $ 4,000,000.0      
Share price (in USD per share) | $ / shares         $ 3.10      
Unrealized (gains) losses of MRI investment $ 2,200,000